jw-therapeutics

JW Therapeutics, a clinical stage biopharmaceutical company focused on developing, manufacturing and commercializing cell therapies for patients in China, acquired Syracuse Biopharma (Hong Kong) Limited, which includes the license for Eureka Therapeutics’ ARTEMIS® antibody TCR and solid tumor technology for exclusive use in China and the ASEAN countries.